Skip to Content Facebook Feature Image

John Lee Emphasizes Global Health Collaboration at Asia Summit in Hong Kong

HK

John Lee Emphasizes Global Health Collaboration at Asia Summit in Hong Kong
HK

HK

John Lee Emphasizes Global Health Collaboration at Asia Summit in Hong Kong

2025-05-26 11:34 Last Updated At:11:58

Speech by CE at Asia Summit on Global Health (with photos/video)

Following is the speech by the Chief Executive, Mr John Lee, at the Asia Summit on Global Health today (May 26):

Honourable Vice-minister Cao Xuetao (Vice-minister of the National Health Commission), Deputy Director Yin Zonghua (Deputy Director of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region (HKSAR)), Deputy Commissioner Li Yongsheng (Deputy Commissioner of the Office of the Commissioner of the Ministry of Foreign Affairs of the People's Republic of China in the HKSAR), Dr Peter Lam (Chairman of the Hong Kong Trade Development Council), distinguished guests, ladies and gentlemen,

Good morning. I am delighted to join you all for this year's Asia Summit on Global Health. Delighted to welcome our friends from around the world to Hong Kong.

Global health starts with unity. This spirit of collaboration is as important today as it was in 2021, when this Summit was first launched. It was launched under the cloud of the global pandemic. We don't need any reminding of the dark days of the COVID-19 outbreak. But it is worth recalling that those difficult times also sparked a remarkable period of healthcare innovation and co-operation. These positive trends continue, here today, at this Summit.

I thank all who are attending the Summit - over 2 800 experts from some 40 countries and regions. You are medical professionals, policymakers, academics, heads of pharmaceutical and health tech enterprises, and experts in many other fields.

You are here to explore innovative solutions to chronic diseases, healthcare inequities and the challenges of an ageing population. To share knowledge and explore the promising opportunities in medicine, and medical technology, across Asia and beyond.

These topics, and more, will be under the microscope, during the next two days of high-level panel discussions, networking and deal-making sessions. From a global perspective, the Director-General of the World Health Organization will share with us his views by video in a few minutes.

Under the theme of "Fostering Global Collaboration for a Shared Future", this Summit reaffirms Hong Kong's pivotal role as a leading health innovation hub in the region.

Under the "one country, two systems" principle, Hong Kong enjoys unique connectivity with both Mainland China and the world. As the world's freest economy and one of the top three international financial centres, we offer an efficient, open and fair business environment with robust intellectual property protection. We maintain free flows of information, capital, goods and talent. We are also emerging as a leading hub for scientific innovation, technological advancement and world-class education.

Hong Kong is the only city in Asia with as many as five universities ranked in the top 100 globally. We are home to two of the world's top 40 medical schools, and eight State Key Laboratories in life and health disciplines. This, and more, provides fertile ground for world-class scientific research and medical technology innovation.

Under "one country, two systems", we also enjoy strong support of national strategies, coupled with ever-closer connectivity with our country, China.

The connectivity is fully evident at the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Straddling our boundary with the neighbouring city of Shenzhen, the Co-operation Zone comprises the Hong Kong Park and the Shenzhen Park. It pools together the technological strengths of our two cities.

Our respective, and collective, strengths are recognised internationally, I'm pleased to add. In its annual Global Innovation Index, the World Intellectual Property Organization has ranked the Shenzhen-Hong Kong-Guangzhou science and technology cluster second, globally, for five consecutive years.

It helps that we are core cities in the Guangdong-Hong Kong-Macao Greater Bay Area, or the GBA, a cluster city development that brings together 11 cities in southern China. It has a population of some 87 million, and a GDP that closely rivals the world's 10th-largest economy.

Riding on this synergy with other GBA cities, the Hong Kong Park of the Co-operation Zone is in good shape for its operational phase later this year. We will provide over US$250 million to support the InnoHK research clusters to set up there, and another US$25 million to assist start-ups engaging in life and health technology.

The InnoHK clusters, let me add, now count 29 research centres and laboratories focusing on health tech, artificial intelligence and robotics, each formed by partnering a Hong Kong institution with a Mainland or international institution.

In other news from the Co-operation Zone, the Greater Bay Area International Clinical Trial Institute is now up and running in the Hong Kong Park.

And, just last week, the Institute started a collaboration initiative on clinical trial with our two medical schools. In more than 70 clinical trial projects expected to be launched in the coming year, the Institute will help to co-ordinate in cross-boundary clinical trials, connection with GBA institutions, and more. Well, that's what I call a healthy outcome!

Another key healthcare collaboration is on the registration for drugs and medical devices. Under a special measure of the National Medical Products Administration, several healthcare institutions in Mainland cities of the GBA may now use drugs and medical devices used in Hong Kong, but not yet registered on the Mainland. This accelerated pathway allows for the access of innovative medicines and devices into the Mainland market.

We are now working with Shenzhen to establish a Real-World Study and Application Centre, by year's end, to promote co-operation on the sharing of health and medical data. It would speed up the approval and registration of new drugs in both places.

Hong Kong is committed to establishing its own internationally recognised authority for the registration of drugs and medical devices. We have implemented the "1+" mechanism for the registration of new drugs, vaccines and advanced therapy products. The mechanism allows for a drug to be registered in Hong Kong, once it has been registered with a reference drug regulatory authority, and supported by local clinical data.

These and other efforts will drive the development of Hong Kong into an international health and medical innovation hub. More importantly, they will expedite patients' access to advanced diagnostic and treatment services.

To boost Hong Kong's research prowess, we have launched a subsidy to support local universities in setting up health technology research institutes. With an allocation of some US$770 million, the programme will foster academic collaboration in life and health sciences research.

Beyond funding research, let me add, we are also investing into developing our research talent. As a result, publicly funded PhD places increased by about one-third to 7 200 over the past two academic years. Places under the Hong Kong PhD Fellowship Scheme also saw a one-third rise.

We endeavour to ensure the timely, and efficient, commercial returns from Hong Kong's excellent research outcomes, including healthcare innovations. For this, we have set aside over US$1.2 billion for the Research, Academic and Industry Sectors One-plus Scheme, and another US$1.2 billion for the New Industrialisation Acceleration Scheme. These Schemes support enterprises to adopt new innovations, and set up smart productions facilities, respectively.

Ladies and gentlemen, in fighting a virus, isolation is vital - quarantining the infected to protect the healthy. But in tackling healthcare, trade, and other societal issues, isolation is not the answer. While walls may stem the spread of a disease, they stifle free and open exchange, which is the lifeblood of prosperity.

With unilateralism and protectionism sweeping the world like a contagion, we should remember a fundamental truth: Trade thrives on openness. Much as how a human body can only stay healthy when its interconnected systems work in harmony, our global economy can only prosper with an ecosystem of trust, collaboration and multilateralism. For in trade, as in health, resilience lies not in isolation, but in collaboration. And Hong Kong is here to build meaningful partnerships and innovative co-operations, with all of you.

My thanks to the Hong Kong Trade Development Council for jointly organising this Summit with the HKSAR Government. I encourage all of you to visit the Hong Kong International Medical and Healthcare Fair, another key event of this International Healthcare Week, over the next three days.

As the saying goes, "Laughter is the best medicine". Therefore, while this Summit focuses on the serious topic of global health, I would like to see all of you rejoice here and participate in a happy mood. Find time, also, to relax and enjoy the colourful cultural experiences here in our world city.

I wish you all a very successful Summit, a delightful stay in Hong Kong and, of course, the best of health!

Thank you.

Speech by CE at Asia Summit on Global Health  Source: HKSAR Government Press Releases

Speech by CE at Asia Summit on Global Health Source: HKSAR Government Press Releases

Speech by CE at Asia Summit on Global Health  Source: HKSAR Government Press Releases

Speech by CE at Asia Summit on Global Health Source: HKSAR Government Press Releases

CFS to follow up certain batches of powdered infant and young children formula with possible presence of Cereulide produced by Bacillus cereus

The Centre for Food Safety (CFS) of the Food and Environmental Hygiene Department (FEHD) today (January 10) said that, it took initiative to meet with Nestlé Hong Kong again today, and confirmed the company's today announcement of an additional batch of powdered infant and young children formula suspected to have possibly used the raw material concerned. Nestlé Hong Kong has voluntarily stopped sales, removed from shelves the affected products and has initiated a precautionary recall. The CFS has collected samples of powdered infant and young children formula from the market for Bacillus cereus testing, the test results so far were satisfactory. The Environmental and Ecology Bureau is also closely monitoring the supply situation of other formula milk powder and maintaining communication with other major suppliers. It is noted that there is sufficient formula milk powder to meet the demand.

The Centre for Food Safety (CFS) of the Food and Environmental Hygiene Department (FEHD), Photo source: reference image

The Centre for Food Safety (CFS) of the Food and Environmental Hygiene Department (FEHD), Photo source: reference image

The spokesman said, the CFS has been actively following up on Nestlé company's voluntary and precautionary recalls of certain batches of its powdered infant and young children formula in certain areas in Europe due to possible presence of Cereulide produced by Bacillus cereus in the individual raw material. According to the latest information from Nestlé Hong Kong today, an additional batch of its powdered infant and young children formula imported into Hong Kong might have used the raw material concerned. The CFS had earlier enhanced surveillance in the market and collected a sample from the above batch for testing of Bacillus cereus. The test result of the sample was satisfactory. Nevertheless, as a precautionary measure, Nestlé Hong Kong has voluntarily stopped sales, removed from shelves the affected products and has initiated a precautionary recall.

Product details are as follows:

Product name (Net weight): NAN PRO 1 2 HMO (800g)

Batch number: 51670742F2

Best-before date: June 16, 2027

Place of Origin: Germany

"The CFS met Nestlé Hong Kong again today, urging them to properly handle the product recall issue and respond to public enquiries, in order to safeguard consumers' legitimate rights and interests. In addition, the CFS and Nestlé Hong Kong have jointly followed up, six suspected affected batches of infant and young children formula products that had not entered the market were marked and sealed. An additional 15 batches are currently en route to Hong Kong and will also be marked and sealed upon arrival. The CFS will continue to closely monitor the recall matters and remain fully committed to ensuring food safety, " the spokesman said.

Nestlé Hong Kong has initiated a recall of the affected batches of the products concerned. For enquiries about the recall, members of the public may contact the company through the following channels:

Consumer services hotline: 2599 8874 / 2797 6031/ 2179 8136 (Monday to Sunday, 9am to 9pm)

Email: consumerservices@hk.nestle.com

WhatsApp: 5283 4139 (NESTLÉ® NAN®) / 2599 8871 (Wyeth® Nutrition)

Online form: forms.office.com/e/BhqMhWfsUG?origin=lprLink

Consumers may choose to bring along the products (brand new or opened) for refund at place of purchase, or at exclusive service counters of Nestlé Nutrition Services from January 13 (Tuesday) onwards, to settle the recall and refund of the batches of the products concerned. Details of the exclusive service counters are as follows:

Kowloon Services Counter

Address: G/F, Park Hovan Commercial Building, 18 Hillwood Road, Tsim Sha Tsui, Kowloon (MTR Jordon Station Exit D)

Contact number: 3996 8196

Office hour: Monday to Saturday, 11am to 7.30pm; Sunday, 1pm to 5.30pm (except public holidays)

Hong Kong Services Counter

Address: 1/F, Ka Nin Wah Commercial Building, 423-425 Hennessy Road, Hong Kong (MTR Causeway Bay Station Exit B)

Contact number: 3996 8197

Office hour: Monday to Saturday, 11am to 7.30pm (except Sundays and public holidays)

The CFS, through its Food Incident Surveillance System, noted earlier that certain batches of Nestlé powdered infant formula were being voluntarily recalled in Europe due to possible contamination with Bacillus cereus. Upon learning of the incident, the CFS has immediately initiated follow up actions, published food incident posts to inform the public and the trade about the issue, and has been actively following up on the incident and enhanced surveillance.

Over the past three days (as of 4pm on January 9), the FEHD received a total of 18 food complaints and enquiries suspected to be related to the infant and young children formula products, including one anonymous complaint without contact information. The CFS and the Environmental Hygiene Branch have promptly followed up on all cases, including contacting the parties concerned to obtain details and collecting samples for testing. In addition, the CFS has referred the cases to the health department for follow-up. At present, no food poisoning cases related to the formula have been recorded.

Bacillus cereus is commonly found in the environment. Unhygienic conditions in food processing and storage may give rise to its growth. Cereulide is a heat-stable toxin produced in food by some strains of Bacillus cereus. Consuming food contaminated with excessive Bacillus cereus or its heat-stable toxins may cause gastrointestinal upset such as vomiting and diarrhoea.

The spokesman urged members of the public not to let infants and young children consume the affected batches of the products, and to seek medical treatment for infants or young children who felt unwell after taking the products concerned. The trade should also stop using or selling the affected batches of the products immediately.

"The CFS continues to closely monitor the developments of the situation, follow up and take appropriate action," the spokesman said.

The infant formula of Nestlé, Photo source: online image

The infant formula of Nestlé, Photo source: online image

Recommended Articles